Adaptive resistance to targeted therapies in cancer - Wikidata - wikimedia - TriplyDB

Adaptive resistance to targeted therapies in cancer

Adaptive resistance to targeted therapies in cancer

http://www.wikidata.org/entity/Q26849316

about

Immunotherapy meets targeted therapy: will this team end the war against cancer?Melanoma: oncogenic drivers and the immune system Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network.Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.Perfluorooctanoic acid induces human Ishikawa endometrial cancer cell migration and invasion through activation of ERK/mTOR signaling.Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.Interleukin-6 identified as an important factor in hypoxia- and aldehyde dehydrogenase-based gefitinib adaptive resistance in non-small cell lung cancer cells.Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications.Phenotypic heterogeneity in modeling cancer evolution.Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy.Inhibition of MEK, a canonical KRAS pathway effector in mutant NSCLC

P2860

Q26769721-785889E5-86A5-47A7-9DC4-BDB77AB72B71 Q26775598-8F5C8350-29EC-4186-8136-7D6F7336DBF6 Q36100853-A7346DFC-728B-4B6E-BD4F-6512B1F330EF Q36138884-46A3B837-44DA-4DC7-B998-6D2D81C7F1AF Q36962376-AA206701-5550-48AF-BB3A-8F46EAE88F59 Q37571930-C72C9BB3-85E2-4235-9567-0EB7A268DE85 Q37687025-525B079F-198B-4CF3-B064-26AB112F21C5 Q38685481-6561B5AA-D775-4DE8-9D6C-A517E25F1664 Q41615232-5EEEAC79-20BE-4F92-9054-CD391C1BD32F Q43237713-F7B025E6-CB87-44C6-9A94-E7708BD1DA68 Q47105970-A273E111-2C90-4168-824F-ACA01AF95E39 Q52361534-44FFA13C-AC82-40AF-8683-B0BE7B2D352C Q58562568-B2085A59-8BA3-4EF6-9402-6C78E547B647

P2860

Adaptive resistance to targeted therapies in cancer

http://www.wikidata.org/entity/Q26849316

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Adaptive resistance to targeted therapies in cancer

@ast

Adaptive resistance to targeted therapies in cancer

@en

Adaptive resistance to targeted therapies in cancer

@nl

type

label

Adaptive resistance to targeted therapies in cancer

@ast

Adaptive resistance to targeted therapies in cancer

@en

Adaptive resistance to targeted therapies in cancer

@nl

prefLabel

Adaptive resistance to targeted therapies in cancer

@ast

Adaptive resistance to targeted therapies in cancer

@en

Adaptive resistance to targeted therapies in cancer

@nl

P1433

Q26849316-D5BC5F69-8203-4248-88ED-97710D39D921

P1476

Q26849316-1F475E4A-847C-4BBA-93A1-8D2EDFE8E04F

P2093

Q26849316-3AD2A3EB-FADF-40D9-A901-11E9E7D8356C

Q26849316-5C58FD76-695E-4611-8681-256537461C73

Q26849316-745EAAC4-6035-4B5E-AF08-2CA7619609DC

Q26849316-752754DE-D5B1-4CE0-A488-B9906F6B1527

Q26849316-75F2D6F6-153E-4CF2-91CB-9A023784758B

Q26849316-AF22EA78-1E16-4B0D-94FA-5948BF2475DB

Q26849316-BF1471C8-76C8-4A6E-B913-8F214B123317

Q26849316-C5AEF5FB-3AF9-46BC-B130-1C43F94B3509

Q26849316-D16E9BE5-4B81-4B04-AEFC-B5422361A52E

Q26849316-DE562DFA-8D14-4546-9642-A1BC719AB83B

P2860

Q26849316-0E1E7F4A-28D9-4499-91BB-9A26780B7B3B

Q26849316-23D8745E-C249-4DD4-9C8B-1A9265576D17

Q26849316-262579E4-A769-4A8B-B9EF-6A6B8B058794

Q26849316-3877C2A2-0027-462F-9A6D-54DBDFAEBBEC

Q26849316-3B1F14FE-F055-41AD-997E-5CA368936D4F

Q26849316-4DD84E1C-3FE4-436D-8AB7-D77645FA1A01

Q26849316-539B7493-06B1-47C8-84A1-D0D2918AF710

Q26849316-6489B6BD-E36B-4A69-848F-87826B1E999E

Q26849316-6C44F8F3-FAE3-4ED0-91FD-8963BB3F07DE

Q26849316-7EB09BC3-1DE7-49A0-90E6-B390262A4CD5

P304

Q26849316-767A8AFD-F29C-4388-9516-1C18B4F97970

P31

Q26849316-5C01AD8A-A1E3-4EC3-9B83-A7AD42622658

P356

Q26849316-E4A6BED3-096A-4117-8587-3F2B8E0EB809

P407

Q26849316-F29448E2-434E-4C52-B22B-231626C0B3D5

P433

Q26849316-9E41B450-3981-45E4-A17B-15B0BF8750F6

P478

Q26849316-C9B72A25-D170-4358-A4BE-A80967993056

P50

Q26849316-9E286E1A-32D4-4D9B-8311-1717B7901DC0

P577

Q26849316-F9E5F0FE-54A7-4548-855D-B5DA76EC5EEC

P5875

Q26849316-0796EAC5-8DE0-45A4-8EAA-5DDAD3CF50BE

P698

Q26849316-3BD9162F-19FD-4D62-ABEA-D08C124E65B2

P932

Q26849316-04C7FCA0-5C1D-480B-B88B-895915FF93E8

P356

J.ISSN.2218-6751.2012.12.08

P1433

Translational lung cancer research

P1476

Adaptive resistance to targeted therapies in cancer

@en

P2093

Alejandro Martínez Bueno

http://www.w3.org/2001/XMLSchema#string

Amaya Gasco

http://www.w3.org/2001/XMLSchema#string

Bartomeu Massuti

http://www.w3.org/2001/XMLSchema#string

Carlota Costa

http://www.w3.org/2001/XMLSchema#string

Daniela Morales-Espinosa

http://www.w3.org/2001/XMLSchema#string

Jia Wei

http://www.w3.org/2001/XMLSchema#string

María González Cao

http://www.w3.org/2001/XMLSchema#string

Miguel Angel Molina

http://www.w3.org/2001/XMLSchema#string

Niki Karachaliou

http://www.w3.org/2001/XMLSchema#string

Rafael Rosell

http://www.w3.org/2001/XMLSchema#string

P2860

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

P304

152-159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2218-6751.2012.12.08

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258518119

http://www.w3.org/2001/XMLSchema#string

P698

25806228

http://www.w3.org/2001/XMLSchema#string

P932

4367602

http://www.w3.org/2001/XMLSchema#string